Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Depomed Inc Fell as Much as 13.8% Today

By Maxx Chatsko - Feb 28, 2018 at 3:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced full-year 2017 earnings yesterday after the market closed.

What happened

Shares of specialty pharmaceuticals provider Depomed (ASRT 5.86%) fell nearly 14% today after the company released fourth-quarter and full-year 2017 results after Tuesday's closing bell. The company struggled last year and is currently in the midst of a much-needed turnaround strategy, which was only formally implemented in the final quarter of 2017. Investors were just reminded how long that might take.

Depomed reported total revenue of $381 million last year, to go along with a GAAP net loss of $102 million. While several restructuring moves contributed to the losses -- and their absence should allow for earnings improvement -- the company likely will be clawing its way to profitability in 2018 and beyond. 

As of 3:08 p.m. EST, the stock had settled to an 11.8% loss.

A finger pointing to a negative stock chart on a screen.

Image source: Getty Images.

So what

Wall Street can't exactly say it was surprised by anything in the recent earnings report. Depomed's struggles and turnaround strategy aren't news. And although the decisions that have been made in recent quarters haven't been easy or always well received, management appears to be doing the right thing to secure the long-term viability of the business.

In January of this year Collegium Pharmaceutical agreed to take control of the Nucynta franchise. That will downsize operations for Depomed and provide a minimum royalty stream of $135 million per year for the next four years. The company has also made moves to exit the opioid business to instead focus on specialty drugs with less legal, social, and ethical risks. A newer, smaller corporate headquarters will also help save expenses and refocus the organization. It expects to be fully operational in its new digs by the third quarter of 2018.

Additionally, Depomed announced that manufacturing of Nucynta ER should return to normal by mid-March. The drug is produced in Puerto Rico and has suffered from periodic supply shortages since the last Atlantic hurricane season devastated the island. In other words, all of the recent developments could provide reason for optimism among investors. 

Now what

All that said, even though the company is executing on its turnaround strategy and portfolio reshuffling, 2018 figures to be a rough year for Depomed stock. There's a high degree of uncertainty facing the business, especially surrounding the transition of the Nucynta franchise from direct sales to royalty stream, since it accounted for 63% of total revenue in 2017. Investors are probably better off keeping their distance from this stock until more traction is demonstrated.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Depomed, Inc. Stock Quote
Depomed, Inc.
ASRT
$2.89 (5.86%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.